Navigating the CGT Landscape: Commercial Considerations, Strategic Investments, and Effective Collaborations
Join us for an insightful panel discussion featuring Dan Kirby, Chief Commercial Officer at Orca Bio; Doug Danison, Head of Commercial for Bayer’s Cell and Gene Therapy Unit; and Ted Slocomb, Vice President of Global Commercial Strategy, Value & Access at Kite Pharma. Moderated by Lung-I Cheng, Vice President and Head of Cell and Gene Therapy at Cencora, the panel dives deep into the complexities and nuances of commercializing cell and gene therapies (CGTs).
Key Insights
In this engaging conversation, the panelists share their unique perspectives on commercial strategies and considerations throughout different stages of the CGT lifecycle:
- Diverse perspectives: With representatives from multinational pharma, emerging biotech, and established companies, the panel reflects on their varying approaches and strategies in the CGT market.
- Early engagement: The importance of early stakeholder engagement is emphasized. The panelists highlighted the need to connect with payers, providers, and patient advocacy groups to inform clinical trial designs and establish value propositions that resonate with all parties involved.
- Navigating complexity: The panel discussed the challenges of introducing cell and gene therapies into established treatment algorithms. Understanding the specific patient populations and clearly defining the unique value of CGT solutions is crucial for successful commercialization.
- Strategic collaboration: This panel underscores the significance of cross-functional collaboration, emphasizing that “cell therapy is a team sport,” requiring seamless coordination among commercial, medical, and operational teams to ensure patient access and successful product launches.
- Resource allocation and prioritization: The panelists discuss how to balance immediate resource needs with long-term strategic goals, including the necessity of allowing product teams to manage their budgets and pivot as needed, and how therapy developers need to prioritize their assets as they approach commercialization.
- Manufacturing challenges: Addressing manufacturing scalability is highlighted as a key challenge.
Watch the full recording for a comprehensive understanding of the commercial landscape in cell and gene therapy. Fill out the form below to gain critical insights into strategic investments, effective collaborations, and the best practices that can drive success in the evolving CGT market.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.